

✓  
IN THE CLAIMS

Please amend the claims to read as follows:

33. (Amended) A composition comprising a first [ligand] compound which selectively activates a Retinoid X Receptor[s] in preference to a Retinoic Acid Receptor[s], in combination with a second [ligand] compound which selectively activates a Retinoic Acid Receptor[s] in preference to a Retinoid X Receptor[s].

Sub  
E1  
34. (Amended) A composition comprising a first [ligand] compound which selectively activates a Retinoid X Receptor[s] in preference to a Retinoic Acid Receptor[s], in combination with a second [ligand] compound which activates one or more intracellular receptors other than a Retinoid X Receptor[s].

§  
35. (Amended) The composition of claim 33 or 34 wherein the physiological effect in mammals produced by said composition at a given concentration is greater than the additive effect achieved utilizing each said [ligand] compound alone at said concentration.

Sub  
E2  
36. (Amended) A pharmaceutical composition comprising in a pharmaceutically acceptable vehicle for enteral, parenteral, or topical administration a first [ligand] compound which selectively activates a Retinoid X Receptor[s] in preference to a Retinoic Acid Receptor[s], in combination with a second [ligand] compound which selectively activates one or more intracellular receptors other than a Retinoid X Receptor[s].

*Sub 1 concluded*  
*37* (Amended) The pharmaceutical composition of claim ~~36~~<sup>4</sup> wherein said second [ligand] compound selectively activates a Retinoic Acid Receptor[s] in preference to a Retinoid X Receptor[s].

*Sub 2*  
*39* (Amended) The method of claim [38] ~~40~~<sup>6</sup> wherein said second [ligand] compound selectively activates a Retinoic Acid Receptor[s] in preference to a Retinoid X Receptor[s].

*Sub 3*  
*43*  
*43*  
40. (Twice Amended) A method for modulating a process mediated by intracellular receptors, said method comprising causing said process to be conducted in the presence of a first compound which selectively activates a Retinoid X Receptor in preference to Retinoic Acid Receptors, in combination with a second compound which activates an intracellular receptor other than Retinoid X Receptors, said activated intracellular receptor forming a dimer with said activated Retinoid X Receptor, and wherein the biological effect in a patient produced by said first and second compounds at a given concentration is equal to or greater than the additive effect achieved utilizing each said first and second compounds alone at said concentration, and [The method of claim 38] wherein said process is the in vivo modulation of lipid metabolism, in vivo modulation of skin-related processes, in vivo modulation of autoimmune diseases, in vivo modulation of fatty acid metabolism, in vivo modulation of malignant cell development, in vivo

3 Sub  
concluded

modulation of premalignant lesions, or in vivo modulation of  
programmed cell death.

8-41<sup>6</sup> (Amended) The method of claim [38] ~~40~~<sup>6</sup> wherein said  
[composition is] first and second compounds are present at a  
concentration at which neither said first nor second [ligand]  
compound would alone produce a significant therapeutic response.

9-42<sup>6</sup> (Amended) The method of claim [38] ~~40~~<sup>6</sup> wherein said  
second [ligand] compound activates a peroxisome proliferator  
activated receptor[s].

10  
43<sup>6</sup> (Amended) The method of claim [38] ~~40~~<sup>6</sup> wherein said  
second [ligand] compound activates a Vitamin D receptor[s].

11  
44<sup>6</sup> (Amended) The method of claim [38] ~~40~~<sup>6</sup> wherein said  
second [ligand] compound activates a thyroid hormone receptor[s],  
HNF4 receptor[s], or a member[s] of the COUP family of receptors.

✓  
Please add new claims 47 and 48 as follows:

154-47<sup>6</sup> The method of claim ~~40~~<sup>6</sup> wherein said first and second  
compounds are administered as a single composition.